Innovation Tracking Factbook 2018: An Assessment of the Pharmaceutical Pipeline

Publisher Name :
Date: 14-Dec-2018
No. of pages: 57

Innovation Tracking Factbook 2018: An Assessment of the Pharmaceutical Pipeline

Summary

GBI Research's latest report "Innovation Tracking Factbook 2018: An Assessment of the Pharmaceutical Pipeline" is a comprehensive, granular analysis of the 25,284 products currently in the pharmaceutical industry pipeline, from the Discovery stage through to Pre-registration and split into key therapy areas and indications.

This pipeline is also benchmarked against its size across each segment compared from Q1 2015 to Q3 2018. In addition, a detailed contextual analysis of the drivers of this pipeline in key therapy areas and an assessment of the level of first-in-class innovation is also provided. Innovation in developing new products is the key element in growth in the pharmaceutical industry.

The market is highly research-intensive, powered by high R&D investment, and it possesses a strong product pipeline to maintain growth and ensure long-term revenue generation. The perks of successful innovation are high, and without successful innovation companies would see a long decline in their growth. A particular focus of this report is placed on analysis of the development of innovative drugs, specifically first-in-class innovation.

Over recent decades, in addition to an increase in the yearly number of new chemical entity approvals by the FDA, the number and proportion of these approvals that were first-in-class at the time of approval have also increased. The proportion of first-in-class approvals has increased steadily most years since 2002.

Scope

- What is the current size and composition of the pharmaceutical industry pipeline and how has it changed in the last four years? What can we learn from this?

- The largest therapy area, by a substantial margin, is oncology, and, with growth in the pipeline sizes for all major oncology indications since Q1 2015, this trend appears set to continue. Why is this case?

- What is the overall advantage for companies including first-in-class product developments in their pipeline portfolio, rather than opting for better-characterized established molecular targets?

- What factors have been driving the increasing number of first-in-class product approvals over recent decades?

- What key discernible trends have appeared in the strategic consolidations landscape in the past decade and which disease areas have been most active?

Reasons to buy

- Achieve an up-to-date understanding of the landscape of the overall pharmaceutical pipeline, on both a broad and granular level; this also provides a highly accessible reference which is useful in any pharmaceutical strategic decision making process

- Benchmark key therapy areas and indications in terms of the number of pipeline products and level of innovation, and assess one's own strategic positioning against this backdrop

- Understand the contemporary role and importance of radical and incremental innovation within the various disease areas and indications

- Make key decisions about the role of innovation within one's own pipeline portfolio

Innovation Tracking Factbook 2018: An Assessment of the Pharmaceutical Pipeline

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 4
1.2 List of Figures 4
2 Introduction 6
2.1 Increasing Cost of Drug Development 9
2.2 Most Drugs Fail to Recuperate R&D Costs 10
2.3 Contracting Life Cycles for Approved Products 11
2.4 The Case for First-in-Class Pharmaceutical Innovation 13
2.5 Status of Innovation in Rare Diseases 14
2.6 Conclusion 16
3 Assessment of Pharmaceutical Industry Pipeline 17
3.1 Pipeline and Clinical Trials Landscape by Therapy Area 18
3.2 Pipeline by Stage of Development 24
3.3 Pipeline by Molecule Type 26
3.4 Key Therapy Areas by Indication 30
3.4.1 Oncology 30
3.4.2 Infectious Diseases 32
3.4.3 Central Nervous System 34
3.4.4 Immunology 36
3.5 Conclusion 38
4 Assessment of Innovation in the Pharmaceutical Industry Pipeline 39
4.1 First-in-Class Innovation by Stage of Development 42
4.2 Key Therapy Areas by Indication 43
4.2.1 Oncology 43
4.2.2 Infectious Diseases 46
4.2.3 Central Nervous System 49
4.2.4 Immunology 52
4.3 Conclusion 54
5 Appendix 55
5.1 References 55
5.2 Abbreviations 56
5.3 Contact Us 56
5.4 Disclaimer 57

1.1 List of Tables
Table 1: Trends in Clinical Trial Protocol Complexity, 2001-2015 9
Table 2: Pipeline Products by Therapy Area, 2015-Q3 2018 20
Table 3: Number of Clinical Trials Initiated by Therapy Area, 2007-2017 23
Table 4: Pipeline Products by Therapy Area and Stage of Development, Q3 2018 26
Table 5: Pipeline Products by Therapy Area and Molecule Type, Q3 2018 29
Table 6: First-in-Class Pipeline Products by Therapy Area, Q1 2015-Q3 2018 41
Table 7: First-in-Class Oncology Pipeline Products by Indication, Q1 2015-Q3 2018 45
Table 8: First-in-Class Infectious Diseases Pipeline Products by Indication, Q1 2015-Q3 2018 48
Table 9: First-in-Class Central Nervous System Disorder Pipeline Products by Indication, Q1 2015-Q3 2018 51
Table 10: First-in-Class Immunology Pipeline Products by Indication, Q1 2015-Q3 2018 54

1.2 List of Figures
Figure 1: US Life Expectancy by Sex, 1950-2017 6
Figure 2: FDA Approvals, 1993-2018 8
Figure 3: Average Cost of Developing a Novel Drug ($m), 1970-2016 9
Figure 4: Projected R&D Returns (%), 2010-2017 10
Figure 5: Drivers of Shortened Pharmaceutical Product Life Cycles, 1970-2011 11
Figure 6: Patent Challenges by Generic Companies 12
Figure 7: FDA Approvals by Innovation Status, 1987-2017 13
Figure 8: Average Sales of First-in-Class and Non-First-in-Class Products After Launch ($m), 2006-2014 14
Figure 9: Average Projected Sales of First-in-Class and Non-First-in-Class Products Launched in 2015 ($m), 2016-2022 14
Figure 10: FDA Orphan Drug Approvals, 1983-2017 15
Figure 11: Pipeline Products by Stage and Molecule Type, Q3 2018 17
Figure 12: Pipeline Products by Therapy Area, Q3 2018 18
Figure 13: Overall Pipeline, Number of Products and Pipeline Growth by Therapy Area, Q1 2015-Q3 2018 19
Figure 14: Number of Clinical Trials Initiated, 2007-2017 21
Figure 15: Number of Clinical Trials Initiated by Therapy Area, 2007-2017 22
Figure 16: Pipeline Products by Therapy Area and Stage of Development (%), Q3 2018 24
Figure 17: Pipeline Products by Therapy Area and Stage of Development, Q3 2018 25
Figure 18: Pipeline Products by Therapy Area and Molecule Type, Q3 2018 27
Figure 19: Pipeline Products by Therapy Area and Molecule Type, Q3 2018 28
Figure 20: Oncology Pipeline Products by Indication, Q3 2018 30
Figure 21: Oncology Pipeline, Number of Products by Indication, Q1 2015-Q3 2018 31
Figure 22: Infectious Disease Pipeline, Number of Products by Indication, Q3 2018 32
Figure 23: Infectious Disease Pipeline, Number of Products and Pipeline Growth by Indication, Q1 2015-Q3 2018 33
Figure 24: Central Nervous System Pipeline, Number of Products by Indication, Q3 2018 34
Figure 25: Central Nervous System Pipeline, Number of Products and Pipeline Growth by Indication, Q1 2015-Q3 2018 35
Figure 26: Immunology Pipeline, Number of Products by Indication, Q3 2018 36
Figure 27: Immunology Pipeline, Number of Products and Pipeline Growth by Indication, Q1 2015-Q3 2018 37
Figure 28: Pipeline Products by Therapy Area and Proportion of Established and First-in-Class Products, Q3 2018 39
Figure 29: First-in-Class Pipeline, Number of Products and Pipeline Growth by Therapy Area, Q1 2015-Q3 2018 40
Figure 30: First-in-class Pipeline Products by Therapy Area and Stage of Development, Q3 2018 42
Figure 31: First-in-Class Oncology Pipeline Products by Indication, Q3 2018 43
Figure 32: First-in-Class Oncology Pipeline, Number of Products and Pipeline Growth by Indication, Q1 2015-Q3 2018 44
Figure 33: First-in-Class Infectious-Diseases Pipeline Products by Indication, Q3 2018 46
Figure 34: First-in-Class Infectious Disease Pipeline, Number of Products and Pipeline Growth by Indication, Q1 2015-Q3 2018 47
Figure 35: First-in-Class Central Nervous System Disorder Pipeline Products by Indication, Q3 2018 49
Figure 36: First-in-Class Central Nervous System Disorder Pipeline, Number of Products and Pipeline Growth by Indication, Q1 2015-Q3 2018 50
Figure 37: First-in-Class Immunology Disorder Pipeline, Number of Products by Indication, Q3 2018 52
Figure 38: First-in-Class Immunology Pipeline, Number of Products and Pipeline Growth by Indication, Q1 2015-Q3 2018 53
  • Global Antioxidant Vitamins Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100
    The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......
  • Global Clavulanate Potassium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86
    The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......
  • Global Amoxicillin Sodium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84
    The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......
  • Global Melatonin Supplements Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106
    The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......
  • Global Sleeping Pills (Prescription Drugs) Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93
    The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......
  • Global Sleeping Pills Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94
    The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
  • Global Zinc Oral Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......
  • Global Zinc Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......
  • Global Anti-Infectives Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78
    The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs